BMS Results Highlight Overreliance On Core Growth Drivers
Pharma & Healthcare / United States / Sun 05 Mar, 2017
Bristol-Myers Squibb's Q117 financial results highlight the importance of the company's core revenue generators, namely Opdivo and Eliquis, in maintaining a robust growth outlook. Impressive revenue gains within the company's immuno-oncology and cardiovascular portfolios will bode well for Bristol-Myers Squibb's outlook for the remainder of 2017